360 related articles for article (PubMed ID: 10571020)
1. MUC1 and cancer.
Taylor-Papadimitriou J; Burchell J; Miles DW; Dalziel M
Biochim Biophys Acta; 1999 Oct; 1455(2-3):301-13. PubMed ID: 10571020
[TBL] [Abstract][Full Text] [Related]
2. MUC1: a target molecule for cancer therapy.
Singh R; Bandyopadhyay D
Cancer Biol Ther; 2007 Apr; 6(4):481-6. PubMed ID: 18027437
[TBL] [Abstract][Full Text] [Related]
3. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.
Bäckström M; Link T; Olson FJ; Karlsson H; Graham R; Picco G; Burchell J; Taylor-Papadimitriou J; Noll T; Hansson GC
Biochem J; 2003 Dec; 376(Pt 3):677-86. PubMed ID: 12950230
[TBL] [Abstract][Full Text] [Related]
4. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.
Müller S; Hanisch FG
J Biol Chem; 2002 Jul; 277(29):26103-12. PubMed ID: 12000758
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycosylation of a synthetic MUC1 mucin-core-related peptide on recognition by anti-mucin antibodies.
Spencer DI; Price MR; Tendler SJ; De Matteis CI; Stadie T; Hanisch FG
Cancer Lett; 1996 Feb; 100(1-2):11-5. PubMed ID: 8620429
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
7. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles.
Engelmann K; Kinlough CL; Müller S; Razawi H; Baldus SE; Hughey RP; Hanisch FG
Glycobiology; 2005 Nov; 15(11):1111-24. PubMed ID: 15972891
[TBL] [Abstract][Full Text] [Related]
8. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
9. Alkali-catalyzed beta-elimination of periodate-oxidized glycans: a novel method of chemical deglycosylation of mucin gene products in paraffin embedded sections.
Hong JC; Kim YS
Glycoconj J; 2000 Oct; 17(10):691-703. PubMed ID: 11425189
[TBL] [Abstract][Full Text] [Related]
10. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
Burchell J; Taylor-Papadimitriou J
Epithelial Cell Biol; 1993 Oct; 2(4):155-62. PubMed ID: 7505698
[TBL] [Abstract][Full Text] [Related]
11. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
12. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
Grinstead JS; Schuman JT; Campbell AP
Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
14. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
15. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
[TBL] [Abstract][Full Text] [Related]
16. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of mucin gene expression in normal and neoplastic tissues.
Ho SB; Niehans GA; Lyftogt C; Yan PS; Cherwitz DL; Gum ET; Dahiya R; Kim YS
Cancer Res; 1993 Feb; 53(3):641-51. PubMed ID: 7678777
[TBL] [Abstract][Full Text] [Related]
18. In vivo glycosylation of MUC1 in airway epithelial cells.
Silverman HS; Sutton-Smith M; Heal P; Parry S; Palmai-Pallag T; Leir SH; Morris HR; Dell A; Harris A
Glycoconj J; 2002 Jul; 19(6):379-84. PubMed ID: 14707484
[TBL] [Abstract][Full Text] [Related]
19. Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen.
Schuman J; Campbell AP; Koganty RR; Longenecker BM
J Pept Res; 2003 Mar; 61(3):91-108. PubMed ID: 12558945
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
Wright SE; Kilinski L; Talib S; Lowe KE; Burnside JS; Wu JY; Dolby N; Dombrowski KE; Lebkowski JS; Philip R
J Immunother; 2000 Jan; 23(1):2-10. PubMed ID: 10687132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
